{{Rsnum
|rsid=1631933
|Gene=SLC25A21
|Chromosome=14
|position=36809759
|Orientation=minus
|GMAF=0.4899
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC25A21
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 16.9 | 44.6 | 38.5
| HCB | 40.9 | 47.7 | 11.4
| JPT | 59.5 | 33.3 | 7.1
| YRI | 30.6 | 41.9 | 27.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 40.9 | 47.7 | 11.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1631933
|Name_s=
|Gene_s=SLC25A21
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.39, combined P value= 4.14E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470240
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1631933
|overall_frequency_n=65
|overall_frequency_d=126
|overall_frequency=0.515873
|n_genomes=45
|n_genomes_annotated=0
|n_haplomes=60
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}